ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$16.53 USD
+0.11 (0.67%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $16.54 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Price, Consensus and EPS Surprise
ACAD 16.53 +0.11(0.67%)
Will ACAD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACAD
Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
Other News for ACAD
Tracking Baker Brothers Portfolio - Q2 2024 Update
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
3 Biotech Names To Target Now